NCI-CONNECT Current Studies
The Comprehensive Oncology Network Evaluating Rare CNS Tumors, or NCI-CONNECT has a number of studies that are open and available for participation and will be adding more.
Outcomes and Risk Project for Patients with Rare CNS Cancers
The project aims to improve our understanding of risk factors associated with the occurrence of rare CNS tumors. Research shows that certain risk factors may increase a person’s chances of developing cancer. Factors can include exposure to chemicals or other substances, personal and family medical history. Through the use of an online platform, participants and families from across the world will be able to participate to provide information that can help clarify the presentation and ongoing health of individuals with these rare diseases. The study represents an ongoing effort to evaluate outcomes in a large group of participants with these rare tumors. Click here to begin the enrollment process >
Assessment at the NIH
Evaluation of the Natural History and Specimen Banking for Patients with CNS Cancers
The study objective is to better understand brain and spinal cord tumors and uncover areas for further research. It also aims to connect patients with doctors who can help them manage their illness and give them new treatment options. Learn more >
Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers
The clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with rare CNS tumors. Learn more >
Carboplatin and Bevacizumab for Patients with Ependymoma
The clinical trial is investigating the combination of bevacizumab and carboplatin to help control recurrent ependymoma. Learn more >
Contact us: email@example.com (link sends e-mail) (240) 760-6530
Follow us: @NIHBrainTumor (link is external) #NCICONNECT
Sign up to receive our newsletters.